Patient-level Costs of Major Cardiovascular Conditions: a Review of the International Literature

Overview

Journal Clinicoecon Outcomes Res

Publisher Dove Medical Press

Specialty Health Services

Date 2016 Oct 6

PMID 27703385

Citations 26

Authors

Gina Nicholson

Shravanthi R Gandra

Ronald J Halbert

Akshara Richhariya

Robert J Nordyke

Affiliations

Soon will be listed here.

Abstract

Objective: Robust cost estimates of cardiovascular (CV) events are required for assessing health care interventions aimed at reducing the economic burden of major adverse CV events. This review synthesizes international cost estimates of CV events.

Methods: MEDLINE database was searched electronically for English language studies published during 2007-2012, with cost estimates for CV events of interest - unstable angina, myocardial infarction, heart failure, stroke, and CV revascularization. Included studies provided at least one estimate of patient-level direct costs in adults for any identified country. Information on study characteristics and cost estimates were collected. All costs were adjusted for inflation to 2013 values.

Results: Across the 114 studies included, the average cost was US $6,466 for unstable angina, $11,664 for acute myocardial infarction, $11,686 for acute heart failure, $11,635 for acute ischemic stroke, $37,611 for coronary artery bypass graft, and $13,501 for percutaneous coronary intervention. The ranges for cost estimates varied widely across countries with US cost estimate being at least twice as high as European Union costs for some conditions. Few studies were found on populations outside the US and European Union.

Conclusion: This review showed wide variation in the cost of CV events within and across countries, while showcasing the continuing economic burden of CV disease. The variability in costs was primarily attributable to differences in study population, costing methodologies, and reporting differences. Reliable cost estimates for assessing economic value of interventions in CV disease are needed.

Citing Articles

Data Mining to Identify the Right Interventions for the Right Patient for Heart Failure: A Real-World Study.

Lee K, Argoubi R, Costantino H Healthc Inform Res. 2025; 31(1):66-87.

PMID: 39973038 PMC: 11854618. DOI: 10.4258/hir.2025.31.1.66.

Economic and equity evaluation of age restrictions on over-the-counter diet pills and muscle-building supplements.

Tschampl C, Tabata-Kelly M, Lee M, Soranno E, Barman U, Raffoul A Health Aff Sch. 2025; 3(1):qxaf002.

PMID: 39845401 PMC: 11751689. DOI: 10.1093/haschl/qxaf002.

Machine learning-driven prediction of medical expenses in triple-vessel PCI patients using feature selection.

Chen K, Huang Y, Liu C, Li S, Chen M BMC Health Serv Res. 2025; 25(1):105.

PMID: 39833782 PMC: 11744989. DOI: 10.1186/s12913-025-12218-6.

Catheter-Based Radiofrequency Renal Denervation in the United States: A Cost-Effectiveness Analysis Based on Contemporary Evidence.

Kandzari D, Cao K, Ryschon A, Sharp A, Pietzsch J J Soc Cardiovasc Angiogr Interv. 2024; 3(10):102234.

PMID: 39525984 PMC: 11549517. DOI: 10.1016/j.jscai.2024.102234.

Cost Offset of Dapagliflozin in the US Medicare Population with Cardio-Kidney Metabolic Syndrome.

Chang R, Miller R, Kwon K, Huang J Adv Ther. 2024; 41(8):3247-3263.

PMID: 38958842 PMC: 11263419. DOI: 10.1007/s12325-024-02919-5.

References

Christensen M, Previgliano I, Capparelli F, Lerman D, Lee W, Wainsztein N . Acute treatment costs of intracerebral hemorrhage and ischemic stroke in Argentina. Acta Neurol Scand. 2008; 119(4):246-53. DOI: 10.1111/j.1600-0404.2008.01094.x. View

Hasan O, Orav E, Hicks L . Insurance status and hospital care for myocardial infarction, stroke, and pneumonia. J Hosp Med. 2010; 5(8):452-9. DOI: 10.1002/jhm.687. View

Chastek B, Riedel A, Wygant G, Hauch O . Evaluation of hospitalization and follow-up care costs among patients hospitalized with ACS treated with a stent and clopidogrel. Curr Med Res Opin. 2009; 25(12):2845-52. DOI: 10.1185/03007990903333017. View

Varani E, Balducelli M, Vecchi G, Aquilina M, Maresta A . Comparison of multiple drug-eluting stent percutaneous coronary intervention and surgical revascularization in patients with multivessel coronary artery disease: one-year clinical results and total treatment costs. J Invasive Cardiol. 2007; 19(11):469-75. View

Shoemaker W . Variability in service line costs for heart failure and shock. Healthc Financ Manage. 2012; 66(6):166. View

Trogdon J, Finkelstein E, Nwaise I, Tangka F, Orenstein D . The economic burden of chronic cardiovascular disease for major insurers. Health Promot Pract. 2007; 8(3):234-42. DOI: 10.1177/1524839907303794. View

Bramkamp M, Radovanovic D, Erne P, Szucs T . Determinants of costs and the length of stay in acute coronary syndromes: a real life analysis of more than 10,000 patients. Cardiovasc Drugs Ther. 2007; 21(5):389-98. DOI: 10.1007/s10557-007-6044-0. View

Allen L, Anstrom K, Horton J, Shaw L, Eisenstein E, Felker G . Relationship between anemia and health care costs in heart failure. J Card Fail. 2009; 15(10):843-9. PMC: 3961827. DOI: 10.1016/j.cardfail.2009.06.435. View

Kastanioti C . Costs, clinical outcomes, and health-related quality of life of off-pump vs. on-pump coronary bypass surgery. Eur J Cardiovasc Nurs. 2006; 6(1):54-9. DOI: 10.1016/j.ejcnurse.2006.04.001. View

10.

Moleerergpoom W, Kanjanavanit R, Jintapakorn W, Sritara P . Costs of payment in Thai acute coronary syndrome patients. J Med Assoc Thai. 2008; 90 Suppl 1:21-31. View

11.

Wilhelmsen L, Welin L, Oden A, Bjornberg A . Saving lives, money and resources: drug and CABG/PCI use after myocardial infarction in a Swedish record-linkage study. Eur J Health Econ. 2009; 11(2):177-84. DOI: 10.1007/s10198-009-0161-6. View

12.

Rihal C, Ryan J, Singh M, Lennon R, Bresnahan J, Liesinger J . Clinical and economic outcomes after introduction of drug-eluting stents. Am J Manag Care. 2010; 16(8):580-7. View

13.

Tiemann O . Variations in hospitalisation costs for acute myocardial infarction - a comparison across Europe. Health Econ. 2008; 17(1 Suppl):S33-45. DOI: 10.1002/hec.1322. View

14.

Gregori D, Desideri A, Bigi R, Petrinco M, Cortigiani L, Zigon G . Proper modeling strategies selection for the assessment of post-infarction costs. Int J Cardiol. 2007; 129(1):53-8. DOI: 10.1016/j.ijcard.2007.05.024. View

15.

Ellis C . Stroke in young adults. Disabil Health J. 2010; 3(3):222-4. DOI: 10.1016/j.dhjo.2010.01.001. View

16.

Engel-Nitz N, Sander S, Harley C, Gomez Rey G, Shah H . Costs and outcomes of noncardioembolic ischemic stroke in a managed care population. Vasc Health Risk Manag. 2010; 6:905-13. PMC: 2952456. DOI: 10.2147/VHRM.S10851. View

17.

Rodriguez A, Maree A, Tarragona S, Fernandez-Pereira C, Santaera O, Rodriguez Granillo A . Percutaneous coronary intervention with oral sirolimus and bare metal stents has comparable safety and efficacy to treatment with drug eluting stents, but with significant cost saving: long-term follow-up results from the randomised, controlled.... EuroIntervention. 2010; 5(2):255-64. DOI: 10.4244/eijv5i2a40. View

18.

Ma Y, Liu Y, Fu H, Wang X, Wu B, Wang S . Evaluation of admission characteristics, hospital length of stay and costs for cerebral infarction in a medium-sized city in China. Eur J Neurol. 2010; 17(10):1270-6. DOI: 10.1111/j.1468-1331.2010.03007.x. View

19.

Haddad N, Bittar E, de Marchi A, Kantorowitz C, Ayoub A, Fonseca M . Hospital costs of coronary artery bypass grafting on elective coronary patients. Arq Bras Cardiol. 2007; 88(4):418-23. DOI: 10.1590/s0066-782x2007000400009. View

20.

Christensen M, Valiente R, Silva G, Lee W, Dutcher S, Rocha M . Acute treatment costs of stroke in Brazil. Neuroepidemiology. 2008; 32(2):142-9. DOI: 10.1159/000184747. View